DE1492015A1 - Verbesserte Verabreichungsform pharmazeutischer Praeparate - Google Patents
Verbesserte Verabreichungsform pharmazeutischer PraeparateInfo
- Publication number
- DE1492015A1 DE1492015A1 DE19631492015 DE1492015A DE1492015A1 DE 1492015 A1 DE1492015 A1 DE 1492015A1 DE 19631492015 DE19631492015 DE 19631492015 DE 1492015 A DE1492015 A DE 1492015A DE 1492015 A1 DE1492015 A1 DE 1492015A1
- Authority
- DE
- Germany
- Prior art keywords
- drug
- ethanol
- composition
- medicament
- practically
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title description 2
- 239000003814 drug Substances 0.000 claims description 66
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 229940079593 drug Drugs 0.000 claims description 52
- 239000000203 mixture Substances 0.000 claims description 29
- 238000002360 preparation method Methods 0.000 claims description 20
- 239000003380 propellant Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 11
- 239000002245 particle Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 7
- 231100000252 nontoxic Toxicity 0.000 claims description 6
- 230000003000 nontoxic effect Effects 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- ZOLBALGTFCCTJF-UHFFFAOYSA-N 4-[1-hydroxy-2-(propan-2-ylamino)ethyl]benzene-1,2-diol;sulfuric acid Chemical compound OS(O)(=O)=O.CC(C)NCC(O)C1=CC=C(O)C(O)=C1.CC(C)NCC(O)C1=CC=C(O)C(O)=C1 ZOLBALGTFCCTJF-UHFFFAOYSA-N 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 4
- 229940018435 isoproterenol sulfate Drugs 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 claims description 2
- 229960003957 dexamethasone Drugs 0.000 claims description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 2
- 229940039009 isoproterenol Drugs 0.000 claims description 2
- PLCQGRYPOISRTQ-FCJDYXGNSA-L dexamethasone sodium phosphate Chemical compound [Na+].[Na+].C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP([O-])([O-])=O)(O)[C@@]1(C)C[C@@H]2O PLCQGRYPOISRTQ-FCJDYXGNSA-L 0.000 claims 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 16
- 238000002664 inhalation therapy Methods 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 102000004877 Insulin Human genes 0.000 description 8
- 108090001061 Insulin Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 229940125396 insulin Drugs 0.000 description 8
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000005507 spraying Methods 0.000 description 5
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 4
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 4
- 239000004546 suspension concentrate Substances 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- VQODGRNSFPNSQE-CXSFZGCWSA-N dexamethasone phosphate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)COP(O)(O)=O)(O)[C@@]1(C)C[C@@H]2O VQODGRNSFPNSQE-CXSFZGCWSA-N 0.000 description 3
- 229960004833 dexamethasone phosphate Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 239000004604 Blowing Agent Substances 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 description 2
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940035722 triiodothyronine Drugs 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- GPHUDPVNXDFRCO-UHFFFAOYSA-N 1-(3,4-dihydroxyphenyl)-2-(propan-2-ylamino)propan-1-one Chemical compound CC(C)NC(C)C(=O)C1=CC=C(O)C(O)=C1 GPHUDPVNXDFRCO-UHFFFAOYSA-N 0.000 description 1
- 206010052613 Allergic bronchitis Diseases 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- WXFIGDLSSYIKKV-RCOVLWMOSA-N L-Metaraminol Chemical compound C[C@H](N)[C@H](O)C1=CC=CC(O)=C1 WXFIGDLSSYIKKV-RCOVLWMOSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- JJCFRYNCJDLXIK-UHFFFAOYSA-N cyproheptadine Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2C=CC2=CC=CC=C21 JJCFRYNCJDLXIK-UHFFFAOYSA-N 0.000 description 1
- 229960001140 cyproheptadine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MZDOIJOUFRQXHC-UHFFFAOYSA-N dimenhydrinate Chemical compound O=C1N(C)C(=O)N(C)C2=NC(Cl)=N[C]21.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 MZDOIJOUFRQXHC-UHFFFAOYSA-N 0.000 description 1
- 229960004993 dimenhydrinate Drugs 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 description 1
- 229960004943 ergotamine Drugs 0.000 description 1
- XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- YFONKFDEZLYQDH-BOURZNODSA-N indaziflam Chemical compound CC(F)C1=NC(N)=NC(N[C@H]2C3=CC(C)=CC=C3C[C@@H]2C)=N1 YFONKFDEZLYQDH-BOURZNODSA-N 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003663 metaraminol Drugs 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Otolaryngology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pulmonology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US241022A US3219533A (en) | 1962-11-29 | 1962-11-29 | Aerosol solid medicament in propellant and low-level ethanol avoiding higher-level ethanol dispersed-solid reflocculation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1492015A1 true DE1492015A1 (de) | 1969-03-06 |
Family
ID=22908922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19631492015 Pending DE1492015A1 (de) | 1962-11-29 | 1963-03-15 | Verbesserte Verabreichungsform pharmazeutischer Praeparate |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US3219533A (enrdf_load_html_response) |
| BE (1) | BE629985A (enrdf_load_html_response) |
| DE (1) | DE1492015A1 (enrdf_load_html_response) |
| GB (1) | GB1018125A (enrdf_load_html_response) |
| NL (1) | NL289785A (enrdf_load_html_response) |
Families Citing this family (150)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3482015A (en) * | 1965-02-08 | 1969-12-02 | Merck & Co Inc | Aerosol composition of phenylephrine tartrate and the production of such |
| US3282791A (en) * | 1965-08-17 | 1966-11-01 | Merck & Co Inc | Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate |
| US3897779A (en) * | 1973-06-27 | 1975-08-05 | American Cyanamid Co | Triamcinolone acetonide inhalation therapy |
| FI63672C (fi) * | 1980-05-19 | 1983-08-10 | Orion Yhtymae Oy | Foerfarande foer framstaellning av en blandning av beklometasondipropionat och triklorfluormetan eller diklordifluormetan |
| GR78151B (enrdf_load_html_response) * | 1982-04-05 | 1984-09-26 | Alcon Lab Inc | |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| US4581225A (en) * | 1984-04-25 | 1986-04-08 | Eli Lilly And Company | Sustained release intranasal formulation and method of use thereof |
| FR2621818B1 (fr) * | 1987-10-19 | 1990-12-14 | Medipro | Medicament comprenant l'association de polymixine b, de netilmicine et d'amphotericine b administre par vaporisation |
| FR2621817B1 (fr) * | 1987-10-19 | 1990-12-14 | Medipro | Medicament comprenant l'association de polymyxine b, de tobramycine et d'amphotericine b administre par vaporisation |
| US5776434A (en) * | 1988-12-06 | 1998-07-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5439670A (en) * | 1989-11-28 | 1995-08-08 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DE4003270A1 (de) * | 1990-02-03 | 1991-08-08 | Boehringer Ingelheim Kg | Neue treibgase und ihre verwendung in arzneimittelzubereitungen |
| US5785952A (en) * | 1990-11-09 | 1998-07-28 | Glaxo Group Limited | Aerosol medicament formulation having a surface coating of surfactant |
| US5919435A (en) * | 1990-11-09 | 1999-07-06 | Glaxo Group Limited | Aerosol formulation containing a particulate medicament |
| WO1993011745A1 (en) * | 1991-12-12 | 1993-06-24 | Glaxo Group Limited | Medicaments |
| IL104068A (en) * | 1991-12-12 | 1998-10-30 | Glaxo Group Ltd | Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant |
| CA2421976C (en) | 1991-12-12 | 2004-04-20 | Glaxo Group Limited | Medicaments |
| US5674471A (en) * | 1991-12-12 | 1997-10-07 | Glaxo Group Limited | Aerosol formulations containing P134a and salbutamol |
| US5736124A (en) * | 1991-12-12 | 1998-04-07 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicament |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| US5653962A (en) * | 1991-12-12 | 1997-08-05 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| US5916540A (en) * | 1994-10-24 | 1999-06-29 | Glaxo Group Limited | Aerosol formulations containing P134A and/or P227 and particulate medicament |
| US5744123A (en) * | 1991-12-12 | 1998-04-28 | Glaxo Group Limited | Aerosol formulations containing P134a and particulate medicaments |
| US7105152B1 (en) | 1991-12-18 | 2006-09-12 | 3M Innovative Properties Company | Suspension aerosol formulations |
| US7101534B1 (en) | 1991-12-18 | 2006-09-05 | 3M Innovative Properties Company | Suspension aerosol formulations |
| ES2099415T3 (es) * | 1991-12-18 | 1997-05-16 | Minnesota Mining & Mfg | Formulaciones de aerosol en suspension. |
| US5603918A (en) * | 1995-06-09 | 1997-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aerosol composition of a salt of ipratropium and a salt of albuterol |
| US8022095B2 (en) * | 1996-08-16 | 2011-09-20 | Pozen, Inc. | Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs |
| US7899511B2 (en) | 2004-07-13 | 2011-03-01 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US9155496B2 (en) | 1997-03-04 | 2015-10-13 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| US7657297B2 (en) | 2004-05-03 | 2010-02-02 | Dexcom, Inc. | Implantable analyte sensor |
| US6949816B2 (en) | 2003-04-21 | 2005-09-27 | Motorola, Inc. | Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same |
| US8465425B2 (en) | 1998-04-30 | 2013-06-18 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8346337B2 (en) | 1998-04-30 | 2013-01-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8974386B2 (en) | 1998-04-30 | 2015-03-10 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US8480580B2 (en) | 1998-04-30 | 2013-07-09 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US20080076997A1 (en) * | 1998-04-30 | 2008-03-27 | Abbott Diabetes Care, Inc. | Analyte monitoring device and methods of use |
| US8688188B2 (en) | 1998-04-30 | 2014-04-01 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US9066695B2 (en) | 1998-04-30 | 2015-06-30 | Abbott Diabetes Care Inc. | Analyte monitoring device and methods of use |
| US6175752B1 (en) | 1998-04-30 | 2001-01-16 | Therasense, Inc. | Analyte monitoring device and methods of use |
| US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
| ATE343374T1 (de) * | 1999-09-11 | 2006-11-15 | Glaxo Group Ltd | Fluticasonpropionat arzneizubereitung |
| US6458387B1 (en) * | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
| US20050048001A1 (en) * | 1999-11-23 | 2005-03-03 | Cripps Alan Leslie | Pharmaceutical formulations of salmeterol |
| DE60019167T2 (de) * | 1999-12-24 | 2006-05-11 | Glaxo Group Ltd., Greenford | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason |
| DE10043509A1 (de) * | 2000-09-01 | 2002-03-14 | Asta Medica Ag | Feste Peptidzubereitungen für die Inhalation und deren Herstellung |
| EP1335661B1 (en) | 2000-10-27 | 2009-05-06 | Baxter Healthcare S.A. | Production of microspheres |
| US6560471B1 (en) | 2001-01-02 | 2003-05-06 | Therasense, Inc. | Analyte monitoring device and methods of use |
| AU2002309528A1 (en) | 2001-04-02 | 2002-10-15 | Therasense, Inc. | Blood glucose tracking apparatus and methods |
| US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
| US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
| US6759029B2 (en) * | 2001-05-24 | 2004-07-06 | Alexza Molecular Delivery Corporation | Delivery of rizatriptan and zolmitriptan through an inhalation route |
| US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
| ES2316571T3 (es) | 2001-05-24 | 2009-04-16 | Alexza Pharmaceuticals, Inc. | Administracion de alprazolam, estazolam, midazolam o triazolam a traves de una via inhalatoria. |
| US7585493B2 (en) | 2001-05-24 | 2009-09-08 | Alexza Pharmaceuticals, Inc. | Thin-film drug delivery article and method of use |
| DE60227659D1 (de) * | 2001-05-24 | 2008-08-28 | Alexza Pharmaceuticals Inc | Verabreichung von antihistaminika durch inhalation |
| CA2446904A1 (en) * | 2001-05-24 | 2003-04-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| US7498019B2 (en) | 2001-05-24 | 2009-03-03 | Alexza Pharmaceuticals, Inc. | Delivery of compounds for the treatment of headache through an inhalation route |
| US20030035774A1 (en) * | 2001-07-18 | 2003-02-20 | Adjei Akwete L. | Salt/ion pair medicinal aerosol formulation |
| GB0208742D0 (en) | 2002-04-17 | 2002-05-29 | Bradford Particle Design Ltd | Particulate materials |
| ES2307779T3 (es) * | 2001-08-16 | 2008-12-01 | Baxter International Inc. | Formulaciones de microparticulas a base de propelentes. |
| EP1944016A1 (en) | 2001-08-16 | 2008-07-16 | Baxter International Inc. | Propellant-based microparticle formulatons |
| WO2003041693A1 (en) * | 2001-11-09 | 2003-05-22 | Alexza Molecular Delivery Corporation | Delivery of diazepam through an inhalation route |
| US8010174B2 (en) | 2003-08-22 | 2011-08-30 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9282925B2 (en) | 2002-02-12 | 2016-03-15 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US9247901B2 (en) | 2003-08-22 | 2016-02-02 | Dexcom, Inc. | Systems and methods for replacing signal artifacts in a glucose sensor data stream |
| US8260393B2 (en) | 2003-07-25 | 2012-09-04 | Dexcom, Inc. | Systems and methods for replacing signal data artifacts in a glucose sensor data stream |
| WO2003080027A1 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of angiogenesis inhibitors |
| US7582284B2 (en) | 2002-04-17 | 2009-09-01 | Nektar Therapeutics | Particulate materials |
| CA2483687A1 (en) | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| NZ540207A (en) | 2002-11-26 | 2008-06-30 | Alexza Pharmaceuticals Inc | Loxapine (2-chloro-11(4-methyl-1-piperazinyl)dibenz(b, f) (1,4) oxazepine) for the manufacture of a medicament for the treatment of headache |
| US7550133B2 (en) | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
| US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
| CA2526475A1 (en) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Optically ignited or electrically ignited self-contained heating unit and drug-supply unit employing same |
| WO2007120442A2 (en) | 2003-07-25 | 2007-10-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8423113B2 (en) | 2003-07-25 | 2013-04-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8332008B2 (en) | 2003-08-01 | 2012-12-11 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7774145B2 (en) | 2003-08-01 | 2010-08-10 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8160669B2 (en) | 2003-08-01 | 2012-04-17 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8275437B2 (en) | 2003-08-01 | 2012-09-25 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8845536B2 (en) | 2003-08-01 | 2014-09-30 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8369919B2 (en) | 2003-08-01 | 2013-02-05 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US20190357827A1 (en) | 2003-08-01 | 2019-11-28 | Dexcom, Inc. | Analyte sensor |
| US8761856B2 (en) | 2003-08-01 | 2014-06-24 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US9135402B2 (en) | 2007-12-17 | 2015-09-15 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US7591801B2 (en) | 2004-02-26 | 2009-09-22 | Dexcom, Inc. | Integrated delivery device for continuous glucose sensor |
| US7494465B2 (en) | 2004-07-13 | 2009-02-24 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US20100168543A1 (en) | 2003-08-01 | 2010-07-01 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US7778680B2 (en) | 2003-08-01 | 2010-08-17 | Dexcom, Inc. | System and methods for processing analyte sensor data |
| US8886273B2 (en) | 2003-08-01 | 2014-11-11 | Dexcom, Inc. | Analyte sensor |
| US20140121989A1 (en) | 2003-08-22 | 2014-05-01 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US7920906B2 (en) | 2005-03-10 | 2011-04-05 | Dexcom, Inc. | System and methods for processing analyte sensor data for sensor calibration |
| US9247900B2 (en) | 2004-07-13 | 2016-02-02 | Dexcom, Inc. | Analyte sensor |
| WO2005051170A2 (en) | 2003-11-19 | 2005-06-09 | Dexcom, Inc. | Integrated receiver for continuous analyte sensor |
| US8423114B2 (en) | 2006-10-04 | 2013-04-16 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US11633133B2 (en) | 2003-12-05 | 2023-04-25 | Dexcom, Inc. | Dual electrode system for a continuous analyte sensor |
| US8364231B2 (en) | 2006-10-04 | 2013-01-29 | Dexcom, Inc. | Analyte sensor |
| US8532730B2 (en) | 2006-10-04 | 2013-09-10 | Dexcom, Inc. | Analyte sensor |
| US8287453B2 (en) | 2003-12-05 | 2012-10-16 | Dexcom, Inc. | Analyte sensor |
| ATE480761T1 (de) | 2003-12-05 | 2010-09-15 | Dexcom Inc | Kalibrationsmethoden für einen kontinuierlich arbeitenden analytsensor |
| EP2301428B1 (en) | 2003-12-09 | 2016-11-30 | Dexcom, Inc. | Signal processing for continuous analyte sensor |
| WO2005065435A2 (en) * | 2003-12-31 | 2005-07-21 | Cydex, Inc. Et Al. | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020299A1 (en) | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid |
| US20070020196A1 (en) * | 2003-12-31 | 2007-01-25 | Pipkin James D | Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension |
| US7637868B2 (en) | 2004-01-12 | 2009-12-29 | Dexcom, Inc. | Composite material for implantable device |
| US8808228B2 (en) | 2004-02-26 | 2014-08-19 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US8792955B2 (en) | 2004-05-03 | 2014-07-29 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7540286B2 (en) | 2004-06-03 | 2009-06-02 | Alexza Pharmaceuticals, Inc. | Multiple dose condensation aerosol devices and methods of forming condensation aerosols |
| US20070045902A1 (en) | 2004-07-13 | 2007-03-01 | Brauker James H | Analyte sensor |
| US8565848B2 (en) | 2004-07-13 | 2013-10-22 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7310544B2 (en) | 2004-07-13 | 2007-12-18 | Dexcom, Inc. | Methods and systems for inserting a transcutaneous analyte sensor |
| US7783333B2 (en) | 2004-07-13 | 2010-08-24 | Dexcom, Inc. | Transcutaneous medical device with variable stiffness |
| US7857760B2 (en) | 2004-07-13 | 2010-12-28 | Dexcom, Inc. | Analyte sensor |
| US8452368B2 (en) | 2004-07-13 | 2013-05-28 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US7581540B2 (en) | 2004-08-12 | 2009-09-01 | Alexza Pharmaceuticals, Inc. | Aerosol drug delivery device incorporating percussively activated heat packages |
| US20090076360A1 (en) | 2007-09-13 | 2009-03-19 | Dexcom, Inc. | Transcutaneous analyte sensor |
| US8133178B2 (en) | 2006-02-22 | 2012-03-13 | Dexcom, Inc. | Analyte sensor |
| US8367734B1 (en) | 2005-08-11 | 2013-02-05 | Amphastar Pharmaceuticals Inc. | Stable epinephrine suspension formulation with high inhalation delivery efficiency |
| US20070185066A1 (en) * | 2005-12-20 | 2007-08-09 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070160542A1 (en) * | 2005-12-20 | 2007-07-12 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| US20070249572A1 (en) * | 2005-12-20 | 2007-10-25 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids |
| US20070178049A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile |
| US20070178050A1 (en) * | 2005-12-20 | 2007-08-02 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids having an increased lung depositon |
| US20070197486A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Methods and systems for the delivery of corticosteroids |
| US20070197487A1 (en) * | 2005-12-20 | 2007-08-23 | Verus Pharmaceuticals, Inc. | Systems and methods for the delivery of corticosteroids having an increased lung deposition |
| US9757061B2 (en) | 2006-01-17 | 2017-09-12 | Dexcom, Inc. | Low oxygen in vivo analyte sensor |
| WO2007102842A2 (en) | 2006-03-09 | 2007-09-13 | Dexcom, Inc. | Systems and methods for processing analyte sensor data |
| US20080071157A1 (en) | 2006-06-07 | 2008-03-20 | Abbott Diabetes Care, Inc. | Analyte monitoring system and method |
| US20070286814A1 (en) * | 2006-06-12 | 2007-12-13 | Medispray Laboratories Pvt. Ltd. | Stable aerosol pharmaceutical formulations |
| CN101677954A (zh) * | 2007-02-11 | 2010-03-24 | Map药物公司 | 治疗性施用dhe用于快速减轻偏头痛而使副作用分布最小化的方法 |
| EP2121088B1 (en) | 2007-03-09 | 2016-07-13 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| US20080306434A1 (en) | 2007-06-08 | 2008-12-11 | Dexcom, Inc. | Integrated medicament delivery device for use with continuous analyte sensor |
| US12370352B2 (en) | 2007-06-28 | 2025-07-29 | Cydex Pharmaceuticals, Inc. | Nasal and ophthalmic delivery of aqueous corticosteroid solutions |
| EP4159114B1 (en) | 2007-10-09 | 2024-04-10 | DexCom, Inc. | Integrated insulin delivery system with continuous glucose sensor |
| US8597616B2 (en) * | 2007-10-22 | 2013-12-03 | Board Of Regents Of The University Of Texas System | Dry powder drug delivery formulations, methods of use, and devices therefore |
| US8417312B2 (en) | 2007-10-25 | 2013-04-09 | Dexcom, Inc. | Systems and methods for processing sensor data |
| US8040246B2 (en) * | 2007-12-04 | 2011-10-18 | Avaya Inc. | Systems and methods for facilitating a first response mission at an incident scene |
| US8290559B2 (en) | 2007-12-17 | 2012-10-16 | Dexcom, Inc. | Systems and methods for processing sensor data |
| WO2009105709A1 (en) | 2008-02-21 | 2009-08-27 | Dexcom, Inc. | Systems and methods for processing, transmitting and displaying sensor data |
| US8396528B2 (en) | 2008-03-25 | 2013-03-12 | Dexcom, Inc. | Analyte sensor |
| EP3795987B1 (en) | 2008-09-19 | 2023-10-25 | Dexcom, Inc. | Particle-containing membrane and particulate electrode for analyte sensors |
| WO2010111660A1 (en) | 2009-03-27 | 2010-09-30 | Dexcom, Inc. | Methods and systems for promoting glucose management |
| EP3825694B1 (en) | 2011-04-15 | 2023-10-25 | DexCom, Inc. | Advanced analyte sensor calibration and error detection |
| US11331022B2 (en) | 2017-10-24 | 2022-05-17 | Dexcom, Inc. | Pre-connected analyte sensors |
| CA3077720A1 (en) | 2017-10-24 | 2019-05-02 | Dexcom, Inc. | Pre-connected analyte sensors |
| KR102852740B1 (ko) | 2018-02-02 | 2025-08-29 | 알렉스자 파마스티칼즈, 인크. | 전기적 응축 에어로졸 디바이스 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2801201A (en) * | 1953-04-09 | 1957-07-30 | Lincoln Lab Inc | Burn treatment filling for pressure packaged dispenser |
| US2798836A (en) * | 1954-01-18 | 1957-07-09 | American Cyanamid Co | Inhalable live virus veterinary vaccine |
| US2798835A (en) * | 1954-01-18 | 1957-07-09 | American Cyanamid Co | Newcastle disease and infectious bronchitis vaccines and production thereof |
| US2959325A (en) * | 1954-04-29 | 1960-11-08 | Risdon Mfg Co | Method and apparatus for dispensing dry powders |
| US2802772A (en) * | 1954-09-09 | 1957-08-13 | Merck & Co Inc | Aerosols compositions; bomb, and process for treating flocks of chickens |
| US2782975A (en) * | 1955-04-20 | 1957-02-26 | American Cyanamid Co | Sprayable amorphous antibiotic composition, pressurized container with same, and method of preparing |
| BE556587A (enrdf_load_html_response) * | 1957-01-31 | 1957-04-11 | ||
| US2987439A (en) * | 1958-01-07 | 1961-06-06 | William Cooper & Nephews Inc | Method of applying an aerosol to the eye |
| US3073743A (en) * | 1959-07-30 | 1963-01-15 | Upjohn Co | Antiinflammatory steroid acetonide compositions and therapy |
| NL125158C (enrdf_load_html_response) * | 1959-10-01 | |||
| NL262354A (enrdf_load_html_response) * | 1960-03-17 |
-
0
- NL NL289785D patent/NL289785A/xx unknown
- BE BE629985D patent/BE629985A/xx unknown
-
1962
- 1962-11-29 US US241022A patent/US3219533A/en not_active Expired - Lifetime
-
1963
- 1963-03-05 GB GB8798/63A patent/GB1018125A/en not_active Expired
- 1963-03-15 DE DE19631492015 patent/DE1492015A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| BE629985A (enrdf_load_html_response) | |
| NL289785A (enrdf_load_html_response) | |
| US3219533A (en) | 1965-11-23 |
| GB1018125A (en) | 1966-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1492015A1 (de) | Verbesserte Verabreichungsform pharmazeutischer Praeparate | |
| DE69005951T2 (de) | Medikamente enthaltend Salmeterol und Fluticason. | |
| DE69629591T2 (de) | Formulierung zur intranasalen verabreichung | |
| DE69938390T2 (de) | Verwendung einer zusammensetzung welche formoterol und budesonide enthält, zur verhinderung oder behandlung eines akuten astmazustandes | |
| DE69724272T3 (de) | Puderförmige zusammensetzung zur nasalen anwendung | |
| DE60019167T2 (de) | Pharmazeutische aerosol formulierung enthaltend salmeterol und fluticason | |
| DE69721766T2 (de) | Neue arzneiformulierung | |
| DE69233519T2 (de) | Verfahren zur Herstellung von Aerosolzusammensetzungen | |
| DE69132407T2 (de) | Aerosol arzneiformulierungen | |
| DE69432224T2 (de) | Aerosole als darreichungsform mit cfc-freiem treibmittel | |
| DE3335086C2 (enrdf_load_html_response) | ||
| DE69807420T2 (de) | Pharmazeutische aerosolzusammensetzung | |
| DE60126599T2 (de) | Cannabis enthaltende pharmazeutische zusammensetzungen | |
| DE69108200T2 (de) | 3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indol-5-methansulfonamid Sulfat (2:1). | |
| DE69003804T2 (de) | Fentanyl enthaltende aerosolzubereitungen. | |
| DE69523587T2 (de) | Fluticasonpropionat-formulierungen | |
| DE69528769T2 (de) | Aerosolformulierung für arzneimittel enthaltend polyglycolisierte glyzeride | |
| DE69002718T2 (de) | Medikamente. | |
| DE69027220T2 (de) | Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen | |
| EP1335728A1 (de) | Neue arzneimittelkompositionen auf der basis von tiotropiumsalzen und salzen des salmeterols | |
| DE69033112T2 (de) | Zink enthaltende Sprays | |
| DE69705628T2 (de) | Chlorfluorkohlenwasserstoff freie aerosol-arzneizubereitungen enthaltend mometasonfuroat | |
| DE3486191T2 (de) | Arzneimittel mit systematischer anticholinesterasischer, agonistisch-cholinergischer und antimuskariner Wirkung. | |
| EP0277462B1 (de) | Verfahren zur Herstellung nasaler Lösungen enthaltend synthetisches Human calcitonin. | |
| DE2166355C2 (de) | Verwendung von d,1-Sobrerol bei der Balsamtherapie der Atemwege |